Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 17, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs	Director, EVP CSO Pres Regen Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	230,350	$179.13	1,066,484
Nov 30, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	196,430	$28.01	1,066,135
Dec 16, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	42,974	$272.73	1,063,638
Jun 23, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Other acquisition or disposition	--	--	987,483
Nov 30, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	94,551	$58.19	971,584
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	129,902	$8.50	962,943
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,103	$109.29	952,840
Aug 05, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	50,000	$600.06	937,483
Aug 13, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	773	$625.00	936,710
Nov 30, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	3,570	$28.01	928,701

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media